NEKTAR THERAPEUTICS Uncategorized Contracts & Agreements

40 Contracts & Agreements

Recent Contracts

Letter Agreement dated as of September 6, 2023 by and between Bristol-Myers Squibb and Company and Nektar Therapeutics (Filed With SEC on November 8, 2023)
Co-Development Agreement, dated as of February 1 (Filed With SEC on February 26, 2021)
Description of Securities (Filed With SEC on February 28, 2020)
Investor Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics (Filed With SEC on May 10, 2018)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
AMENDEDAND RESTATED COMPENSATIONPLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on December 14, 2009)
LICENSEAGREEMENT byand between ASTRAZENECAAB and NEKTARTHERAPEUTICS DATE:September20, 2009 (Filed With SEC on November 5, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
Current assets (Filed With SEC on May 9, 2008)
Current assets (Filed With SEC on May 9, 2008)
NEKTAR THERAPEUTICS (Filed With SEC on March 1, 2007)
EXHIBIT A EMPLOYEE AGREEMENT (Filed With SEC on January 9, 2007)
[Nektar Letterhead] (Filed With SEC on March 16, 2006)
[Nektar Therapeutics Letterhead] (Filed With SEC on March 8, 2006)
NEKTAR THERAPEUTICS (Filed With SEC on March 21, 2005)
THECORPORATEPLAN FOR RETIREMENTSM (PROFITSHARING/401(K) PLAN) A FIDELITYPROTOTYPE PLAN Non-StandardizedAdoption Agreement No. 001 For use With FidelityBasic Plan Document No. 02 (Filed With SEC on August 5, 2004)
THE CORPORATEPLAN FOR RETIREMENTSM FIDELITY BASIC PLAN DOCUMENT NO. 02 2003 FMR Corp. All rights reserved. (Filed With SEC on August 5, 2004)
RESALEREGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 3, 2003)
RESALEREGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 10, 2003)
EMPLOYEERELOCATION REPAYMENT AGREEMENT (Filed With SEC on May 13, 2003)
NUMBER (Filed With SEC on January 23, 2003)
CONFIDENTIAL (Filed With SEC on November 14, 2002)